Immuno-persistence after the 4th and 5th dose of inactivated polio vaccines in school-aged children

Immuno-persistence after the 4th and 5th dose of inactivated polio vaccines in school-aged children | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Brief Communication Immuno-persistence after the 4 th and 5 th dose of inactivated polio vaccines in school-aged children Kathy Leung, Chrissy Wing Kwan Pang, Tiffany Hoi Ki Lo, Juan Vargas-Zambrano, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3890516/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Despite decades of research, questions remain about the persistence of neutralising antibodies (nAb) and serological correlates of polio vaccine efficacy. In a cross-sectional study among 299 children in Hong Kong, we estimated that the mean nAb titres against polioviruses type 1, 2 and 3 (PV1, PV2 and PV3) one month after receiving the 4 th dose of inactivated polio vaccine (IPV) at 19 months of age were 2,068 (95% credible interval: 1,517 – 2,864), 4,705 (3,439 – 6,436) and 2,758 (1,894 – 4,086), but declined substantially in 4 years to 268 (222 – 325), 751 (630 – 900), and 411 (323 – 521), respectively. Administration of the 5 th dose of IPV restored nAb titres among children aged 6-7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272 – 462), 538 (427 – 681), and 548 (378 – 786) against PV1, PV2, and PV3 at 4 years post the 5 th dose. We estimated that the proportion of children who were seroprotected against PV1, PV2 and PV3 would drop below 90% at: (i) 8.2, 10.8, 8.7 years after the 4 th dose; and (ii) 11.6, 11.2, 11.0 years after the 5 th dose, highlighting the importance of maintaining populational immune persistence at high nAb levels. Health sciences/Health care/Disease prevention/Preventive medicine Health sciences/Health care/Public health/Epidemiology Full Text Additional Declarations There is NO Competing Interest. Supplementary Files 6Datasetcsv1.csv Dataset 1 3SupplementaryInformation.pdf Supplementary Information Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3890516","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Brief Communication","associatedPublications":[],"authors":[{"id":269500693,"identity":"cd56d850-61db-496a-a2e8-fd6a3b9411f8","order_by":0,"name":"Kathy Leung","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAw0lEQVRIiWNgGAWjYBACCQYGxgMgBr8EG5DZkECUFgawFskZJGsxuEGsFsn+0wkHPrbdsdt8uy1NgnFHGmEt0hK5Gw7ObHuWvO3OsWMSjGdyCGuRk+DdcJi37XCy2Y30NgnGtgoitPCf3XD4L1CL8QxitUgz5G44zNh22M5AIg3osDYiHCY5A+iXnnOHEyRupCVbJLYR4X2J82c3PvhRdtief0aa4Y2PbcmEtcBAYgOITCBeAwODPSmKR8EoGAWjYIQBAKhEQLPEGDgmAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0003-4777-388X","institution":"The University of Hong Kong","correspondingAuthor":true,"prefix":"","firstName":"Kathy","middleName":"","lastName":"Leung","suffix":""},{"id":269500694,"identity":"24d78e23-9d75-4ef7-b37a-73dc5c552a8c","order_by":1,"name":"Chrissy Wing Kwan Pang","email":"","orcid":"https://orcid.org/0009-0005-5717-3695","institution":"The University of Hong Kong","correspondingAuthor":false,"prefix":"","firstName":"Chrissy","middleName":"Wing Kwan","lastName":"Pang","suffix":""},{"id":269500695,"identity":"5302c7a1-545b-4270-83bf-1c58df8e78e8","order_by":2,"name":"Tiffany Hoi Ki Lo","email":"","orcid":"","institution":"The University of Hong Kong","correspondingAuthor":false,"prefix":"","firstName":"Tiffany","middleName":"Hoi Ki","lastName":"Lo","suffix":""},{"id":269500696,"identity":"568a0359-46ff-4d65-a95b-604c6d55b15a","order_by":3,"name":"Juan Vargas-Zambrano","email":"","orcid":"","institution":"Sanofi Pasteur","correspondingAuthor":false,"prefix":"","firstName":"Juan","middleName":"","lastName":"Vargas-Zambrano","suffix":""},{"id":269500697,"identity":"ec4e0ba5-b05d-44d3-b886-cbfd7718a2e3","order_by":4,"name":"Céline Petit","email":"","orcid":"","institution":"Sanofi Pasteur","correspondingAuthor":false,"prefix":"","firstName":"Céline","middleName":"","lastName":"Petit","suffix":""},{"id":269500698,"identity":"56628831-f79e-489d-b88b-70dedeade4ff","order_by":5,"name":"Tommy Tsan-Yuk Lam","email":"","orcid":"https://orcid.org/0000-0002-9769-1527","institution":"The University of Hong Kong","correspondingAuthor":false,"prefix":"","firstName":"Tommy","middleName":"Tsan-Yuk","lastName":"Lam","suffix":""},{"id":269500699,"identity":"02889de5-f513-4b2d-97e6-04cea4168cf2","order_by":6,"name":"Eric Lau","email":"","orcid":"https://orcid.org/0000-0002-6688-9637","institution":"University of Hong Kong","correspondingAuthor":false,"prefix":"","firstName":"Eric","middleName":"","lastName":"Lau","suffix":""},{"id":269500700,"identity":"fc1fd399-c77f-492d-92b8-5a9186438636","order_by":7,"name":"Joseph Wu","email":"","orcid":"https://orcid.org/0000-0002-3155-5987","institution":"The University of Hong Kong","correspondingAuthor":false,"prefix":"","firstName":"Joseph","middleName":"","lastName":"Wu","suffix":""}],"badges":[],"createdAt":"2024-01-23 08:51:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3890516/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3890516/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":50344739,"identity":"70792ce7-63d0-439b-b615-c8e267c4af7b","added_by":"auto","created_at":"2024-01-30 06:09:17","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":892886,"visible":true,"origin":"","legend":"","description":"","filename":"2manuscriptpolioseroprev.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3890516/v1_covered_1ea2b7e0-2360-4445-9d6a-7ad0b31f6649.pdf"},{"id":50344491,"identity":"5bd012ee-3fc3-4317-b9d8-f90419180084","added_by":"auto","created_at":"2024-01-30 06:01:07","extension":"csv","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":55072,"visible":true,"origin":"","legend":"Dataset 1","description":"","filename":"6Datasetcsv1.csv","url":"https://assets-eu.researchsquare.com/files/rs-3890516/v1/2eac506af1838a3f94a94613.csv"},{"id":50344492,"identity":"aebcb323-2413-4274-af4a-51d80eba2748","added_by":"auto","created_at":"2024-01-30 06:01:07","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":1202318,"visible":true,"origin":"","legend":"Supplementary Information","description":"","filename":"3SupplementaryInformation.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3890516/v1/14e79feed8d47474ef86f9d2.pdf"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"\u003cp\u003eImmuno-persistence after the 4\u003csup\u003eth\u003c/sup\u003e and 5\u003csup\u003eth\u003c/sup\u003e dose of inactivated polio vaccines in school-aged children\u003c/p\u003e","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-3890516/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3890516/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eDespite decades of research, questions remain about the persistence of neutralising antibodies (nAb) and serological correlates of polio vaccine efficacy. In a cross-sectional study among 299 children in Hong Kong, we estimated that the mean nAb titres against polioviruses type 1, 2 and 3 (PV1, PV2 and PV3) one month after receiving the 4\u003csup\u003eth\u003c/sup\u003e dose of inactivated polio vaccine (IPV) at 19 months of age were 2,068 (95% credible interval: 1,517 – 2,864), 4,705 (3,439 – 6,436) and 2,758 (1,894 – 4,086), but declined substantially in 4 years to 268 (222 – 325), 751 (630 – 900), and 411 (323 – 521), respectively. Administration of the 5\u003csup\u003eth\u003c/sup\u003e dose of IPV restored nAb titres among children aged 6-7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272 – 462), 538 (427 – 681), and 548 (378 – 786) against PV1, PV2, and PV3 at 4 years post the 5\u003csup\u003eth\u003c/sup\u003e dose. We estimated that the proportion of children who were seroprotected against PV1, PV2 and PV3 would drop below 90% at: (i) 8.2, 10.8, 8.7 years after the 4\u003csup\u003eth\u003c/sup\u003e dose; and (ii) 11.6, 11.2, 11.0 years after the 5\u003csup\u003eth\u003c/sup\u003e dose, highlighting the importance of maintaining populational immune persistence at high nAb levels.\u003c/p\u003e","manuscriptTitle":"Immuno-persistence after the 4th and 5th dose of inactivated polio vaccines in school-aged children","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-01-30 06:01:02","doi":"10.21203/rs.3.rs-3890516/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2681f220-672e-42b7-8e67-b020b008f7fe","owner":[],"postedDate":"January 30th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":28446924,"name":"Health sciences/Health care/Disease prevention/Preventive medicine"},{"id":28446925,"name":"Health sciences/Health care/Public health/Epidemiology"}],"tags":[],"updatedAt":"2024-02-28T12:22:53+00:00","versionOfRecord":[],"versionCreatedAt":"2024-01-30 06:01:02","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3890516","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3890516","identity":"rs-3890516","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}